Background
==========

Malaria is responsible for more than one million deaths annually, the majority of which occur in sub-Saharan Africa, with *Plasmodium falciparum* as the predominant organism \[[@B1]\]. In non-endemic regions, most cases occur in non-immune or semi-immune travellers returning from endemic countries who do not adhere to malaria chemoprophylaxis \[[@B2],[@B3]\]. Such cases may be particularly severe, with in-hospital mortality rates reported as 11 to 40% \[[@B2],[@B4]-[@B6]\]. Acute respiratory distress syndrome (ARDS), which may develop in either the acute or late phases of infection, has been reported in 5 to 25% of adults with severe *P. falciparum* and in 1 to 10% of patients with severe *Plasmodium vivax*\[[@B1]\], with an attributable mortality of 20% in developed countries \[[@B5]\].

Extracorporeal membrane oxygenation (ECMO), referring to an extracorporeal circuit that directly oxygenates and removes carbon dioxide from the blood, may be considered in patients with ARDS whose pulmonary injury is so severe that positive-pressure ventilation alone is insufficient to maintain adequate gas exchange, or when adherence to lung-protective ventilation strategies results in unacceptable levels of hypercapnia and acidaemia \[[@B7]\]. In most cases of ECMO for severe ARDS, venovenous ECMO is utilized, in which blood is withdrawn from and returned to a central vein. Recently, there has been increasing interest in ECMO as a result of advances in extracorporeal technology, with more efficient oxygenators and lower rates of complications, along with several reports of improved survival with ECMO for severe ARDS \[[@B8]-[@B11]\]. However, reports of ECMO for severe ARDS in patients with malaria are uncommon, with only two cases reported separately in the literature \[[@B5],[@B12]\], as well as one case of extracorporeal carbon dioxide elimination \[[@B13]\]. In the present report, a series of three cases of malaria complicated by severe ARDS refractory to conventional treatment and supported with ECMO is presented.

Methods
=======

Case 1
------

A 53-year-old Portuguese man with a history of diabetes and myocardial infarction presented with five days of fever, chills, headache and myalgias (Table [1](#T1){ref-type="table"}). The patient had been living in Angola, and he was not taking any malaria prophylaxis. The patient was evaluated at Hospital S João (Porto, Portugal), where vital signs and physical examination were unremarkable. Blood smear revealed *P. falciparum* (2% parasitaemia) and severe thrombocytopaenia (17,000 platelets/μl). The patient was initially admitted in a regular ward and oral quinine sulphate plus doxycycline were administered. However, shortly after admission, he developed vomiting with intolerance to oral drugs. In that context, intravenous quinine and doxycycline were started. No arrhythmia occurred during quinine treatment. The patient developed progressive hypoxemic respiratory failure requiring invasive mechanical ventilation (IMV) on hospital day 3 despite antimicrobials, diuresis, and clearance of his parasitaemia (Table [2](#T2){ref-type="table"}). Blood cultures (obtained on hospital and ICU admission), urine culture and pneumococcal and Legionella urinary antigen tests, bacteriologic and virologic exams of tracheal secretions and bronchoalveolar lavage (performed immediately after tracheal intubation) were all negative. His thoracic CT scan revealed bilateral parenchymal consolidation in gravity-dependent areas and ground-glass-appearing opacities of lung parenchyma, compatible with severe ARDS (Figure [1](#F1){ref-type="fig"}A). Echocardiography was performed showing preserved ejection fraction and normal diastolic function. Moreover, plasma BNP was not elevated (98 pg/ml). Haemodynamic monitoring using the transpulmonary thermodilution technique and arterial pulse contour analysis (PiCCO^®^; Philips) was also performed before ECMO treatment, the results being consistent with ARDS (increased (23.7; normal range 3.0-7.0 ml/kg) extravascular lung water index (ELWI) and increased (6.6; normal range 1.0-3.0) pulmonary vascular permeability index (PVPI)), without intravascular volume overload (decreased (672; normal range 850--1000 ml/m^2^) intrathoracic blood volume index (ITBI) and decreased (538; normal range 680--800 ml/m^2^) global enddiastolic volume index (GEDI)). Cardiac index (3.6; normal range 3.0 - 5.0 l/min/m^2^) and systemic vascular resistance index (1838; normal range 1700--2400 dyn\*s\*cm^-5^\*m^2^) were also recorded. On day 7 of IMV, his PaO~2~ was 69 mmHg with a FiO~2~ of 1.0 and PEEP of 13 cm of water, without improvement with a conservative strategy of fluid management, prone positioning or corticosteroids. ECMO was initiated with placement of a 21Fr right femoral venous drainage cannula and a 15Fr right internal jugular venous re-infusion cannula. The ventilator was then set to a lung-protective strategy (Table [2](#T2){ref-type="table"}). On hospital day 20, ventilator-associated pneumonia occurred and *Pseudomonas aeruginosa* was isolated in cultures from bronchoalveolar lavage and blood. On hospital day 40 a new episode of VAP occurred and *Escherichia coli* was isolated in cultures from tracheal aspirate and on hospital day 48 septic shock with multi-organ failure supervened and *Pseudomonas aeruginosa* was isolated from the blood and tracheal aspirate. The patient died on hospital day 49 (ECMO day 40; Figure [1](#F1){ref-type="fig"}B). The only ECMO-related complication was thrombus formation in the oxygenator, requiring exchange on ECMO day 29.

###### 

Characteristics of patients with malaria-related severe ARDS requiring ECMO

              **Patient**                     **1**                 **2**                     **3**
  ----------------------------------- --------------------- --------------------- -----------------------------
            **Age (years)**                  **53**                **39**                    **46**
              **Gender**                    **Male**              **Male**                 **Female**
         **Country of origin**             **Angola**          **Mozambique**              **Uganda**
        **Plasmodium species**         ***P. falciparum***   ***P. falciparum***   ***P. vivax and P. ovale***
   **Clinical deterioration (days)**                                                             
    Symptoms to hospital admission              5                     3                        14
       Hospital to ICU admission                2                     3                         4
         ICU admission to ECMO                  9                    14                         1
              IMV to ECMO                       8                    11                         1
           **Murray score**                 **3.75**              **3.75**                   **4.0**
            **Before ECMO**                                                                      
            Prone position                     Yes                   Yes                       No
             Nitric oxide                      No                    No                        Yes
       Renal replacement therapy               No                    No                        No
            **During ECMO**                                                                      
            Prone position                     No                    No                        No
             Nitric oxide                      No                    No                        No
       Renal replacement therapy               Yes                   No                        No
           **APACHE II \***                  **11**                **14**                    **17**
   **Mechanical ventilation (days)**         **48**                **25**                    **17**
            **ECMO (days)**                  **40**                 **7**                    **10**
          **ICU LOS (days)**                 **49**                **46**                    **23**
           **ICU survival**                 **NSurv**             **Surv**                  **Surv**
         **Hospital survival**              **NSurv**             **Surv**                  **Surv**

APACHE II, Acute Physiology and Chronic Health Evaluation II; LOS, length of stay; ECMO, extracorporeal membrane oxygenation; IMV, invasive mechanical ventilation; NSurv, non-survivor; Surv, survivor. \* First day of ICU admission.

###### 

Respiratory and haematologic parameters before, during, and after ECMO

           **Patient**              **1**         **2**         **3**
  ----------------------------- ------------- ------------- -------------
        **ICU admission**                                          
           Ventilation               SB            NIV           IMV
           FiO~2~ (%)                85            50            100
       pH / PaCO~2~ (mmHg)       7.50 / 36.2   7.41 / 39.4     7.41/39
       Haemoglobin (g/dL)           11.4          12.0           9.6
        Parasitaemia (%)          Negative      Negative        0.015
         **Before ECMO**                                           
   PC-peak / VC-plat (cmH~2~O)       32            30            34
        Tidal volume (ml)            420           450           350
         PEEP (cmH~2~O)              13            12            15
     PaO~2~ / FiO~2~ (mmHg)          69            62            69
           FiO~2~ (%)                100           100           100
       pH / PaCO~2~ (mmHg)       7.36 / 72.9   7.35 / 73.1   7.41 / 39.0
      Fluid balance (L/24h)         +0.35         +0.75         +0.52
        **Day 2 on ECMO**                                          
   PC-peak / VC-plat (cmH~2~O)       28            26            26
        Tidal volume (ml)            280           340           210
         PEEP (cmH~2~O)              10            10            10
           FiO~2~ (%)                60            55            40
          ECMO-BF (lpm)              3.0           3.0           3.5
        ECMO-sweep (lpm)             2.0           3.0           3.0
       pH / PaCO~2~ (mmHg)       7.40 / 47.0   7.44 / 54.0   7.45 / 36.0
      Fluid balance (L/24h)         +1.55         +0.85         +2.70
         **End of ECMO**                                           
   PC-peak / VC-plat (cmH~2~O)       31            28            23
        Tidal volume (ml)            110           560           385
         PEEP (cmH~2~O)               8             8            12
           FiO~2~ (%)                60            50            50
          ECMO-BF (lpm)              3.0           3.0           3.3
        ECMO-sweep (lpm)             7.0           2.5           1.5
       pH / PaCO~2~ (mmHg)       7.22 / 33.0   7.43 / 38.5     7.43/42
      Fluid balance (L/24h)         +1.85         +0.80         +0.48
        **ICU discharge**                                          
           Ventilation               NA            SB            SB
           FiO~2~ (%)                NA            27            40
       pH / PaCO~2~ (mmHg)           NA        7.47 / 30.7   7.44 / 38.0

ECMO-BF, blood flow through the ECMO circuit; ECMO-Sweep, sweep gas flow through the ECMO circuit; IVM, invasive mechanical ventilation; NA, not applicable; NIV, non-invasive ventilation; PaCO~2~, arterial carbon dioxide partial pressure; PEEP, positive end-expiratory pressure; PC-peak, peak inspiratory pressure under pressure control ventilation; SB, spontaneous breathing; VC-plat, plateau pressure under volume control ventilation.

![**Thoracic computed tomography (CT) before ECMO implantation (A) and after 40 days of ECMO support (B) in Patient 1.A**. Bilateral parenchymal consolidation in gravity-dependent areas and ground-glass-appearing opacities of lung parenchyma, compatible with severe ARDS. **B**. Extensive parenchymal consolidation and bilateral pleural effusions with associated compression atelectasis after 40 days of VV-ECMO.](1475-2875-12-306-1){#F1}

Case 2
------

A 39-year-old Portuguese man with a history of hypertension and a prior episode of malaria treated as an outpatient, presented with three days of fever, myalgias, headache, nausea and vomiting (Table [1](#T1){ref-type="table"}). The patient had worked for several years in Mozambique, and he was not taking any malaria prophylaxis. On presentation, he was febrile and somnolent. Chest X-ray was normal. Blood smear revealed *P. falciparum* (3% parasitaemia) and thrombocytopaenia (80,000 platelets/μl). Taking into account the presence of vomiting with intolerance to oral drugs, the patient was treated with intravenous quinine and clindamycin. Despite negative cultures and clearance of his parasitaemia, hypoxemic respiratory failure developed on hospital day 6, requiring IMV (Table [2](#T2){ref-type="table"}). Blood cultures (obtained on hospital and ICU admission), urine culture and urinary antigens (pneumococcal and Legionella), bacteriologic and virologic examinations of tracheal secretions and bronchoalveolar lavage (performed immediately after tracheal intubation) were all negative. Chest X-ray showed bilateral infiltrates and echocardiogram was unremarkable (Figure [2](#F2){ref-type="fig"}A). On day 11 of IMV, his PaO~2~ was 62 mmHg despite an FIO~2~ of 1.0, PEEP of 12 cm of water, a conservative strategy of fluid management, prone positioning, and corticosteroids. ECMO was then initiated with a 23Fr drainage cannula in the right femoral vein and 17Fr re-infusion cannula in the right internal jugular vein. The patient was successfully decannulated after seven days of ECMO support and weaned off IMV within the next seven days (Figure [2](#F2){ref-type="fig"}B). There were no ECMO-related complications. He was discharged home two weeks post-ICU discharge, where he has been living independently.

![**Chest X-ray before ECMO implantation (A) and before hospital discharge (B) in Patient 2. A**. Bilateral parenchymal consolidation with air bronchograms, compatible with severe ARDS. **B**. Complete resolution of bilateral infiltrates.](1475-2875-12-306-2){#F2}

Case 3
------

A 46-year-old American woman presented with two weeks of cyclic fevers, night sweats, and myalgias (Table [1](#T1){ref-type="table"}). She had recently returned from Uganda, where she worked in a rural area and was adherent to atovaquone and proguanil malaria prophylaxis. She was treated empirically for chloroquine-resistant *P. falciparum* with oral quinine and doxycycline, however she did not tolerate oral therapy due to nausea and vomiting, and required admission to a local hospital for initiation of intravenous quinidine and clindamycin. Her vital signs, physical exam, and chest X-ray were unremarkable. Initial blood smears showed 0.5% parasitaemia. Once PCR testing confirmed *P. vivax* and *P. ovale* and excluded *P. falciparum*, her treatment was changed to chloroquine; however severe hypoxemic respiratory failure with bilateral infiltrates developed by hospital day 4, requiring IMV, at which point intravenous therapy was resumed. PaO~2~ was 68 mmHg despite an FIO~2~ of 1.0, PEEP of 15 cm of water, a conservative strategy of fluid management and inhaled nitric oxide (iNO) (Table [2](#T2){ref-type="table"}). Echocardiogram demonstrated normal cardiac function. She was transferred to the Columbia University College of Physicians and Surgeons (New York, NY, USA), where she was placed on ECMO with a 27Fr bicaval dual-lumen cannula via the right internal jugular vein under fluoroscopic and echocardiographic guidance \[[@B14],[@B15]\]. Cultures and blood smears in the ICU were negative for organisms. Anti-malarial therapy with intravenous quinidine and doxycycline was continued and she was successfully decannulated on ECMO day 10, and liberated from IMV seven days later. No arrhythmias occurred during quinine treatment. One month post-discharge, she was functioning independently. Two ECMO-related complications occurred: i) migration of the distal end of the cannula into a hepatic vein, identified by transesophageal echocardiogram on ECMO day 2 in the setting of a decrease in blood flow rates, followed by successful repositioning at the bedside; and ii) bleeding from the cannulation site and epistaxis that required a total of 8 units of packed red blood cells in the setting of low-level anticoagulation to maintain ECMO circuit integrity (mean activated partial thromboplastin time 46.5 seconds).

Consent
-------

Informed consent was obtained from the patients for publication of this case series and any accompanying images after explanation of the report objectives.

Discussion
==========

In this report, three cases of imported malaria complicated by severe ARDS supported with ECMO are presented. Severe ARDS may be a complication of *P. falciparum*, *P. vivax* or *P. ovale* infections. In accordance with the WHO guidelines the presence of ARDS is a defining criterion for severe malaria \[[@B16]\]. In all three cases, oxygenation and CO~2~ clearance through the membrane ECMO lung allowed the compliance to protective ventilation of the native lung with low tidal volumes (\<6 ml/kg IBW) and low-fractional oxygen concentrations, limiting ventilator-induced lung injury \[[@B17]\]. However, permissive hypercapnia is frequently necessary to allow low tidal volume protective ventilation in severe ARDS. This could be potentially harmful in patients with severe malaria, given that cerebral oedema with elevated intracranial pressures can complicate cerebral malaria \[[@B18]\] and that hypercapnia causes cerebral vasodilatation and intracranial pressure elevation. Moreover, microvascular congestion and sequestration of parasitized red blood cells was shown to be a common feature in cerebral malaria, leading to impaired tissue perfusion that may cause diffuse cerebral ischemia and increased intracranial blood volume \[[@B19]\]. The use of ECMO in patients with severe malaria, allowing strict control of patient's PaCO2, potentially limits intracranial pressure elevation.

Fluid management is crucial in patients with severe malaria. Taking into account that in these patients pulmonary edema secondary to increased pulmonary vascular permeability has been shown to be frequent, unpredictable and exacerbated by fluid loading, a conservative strategy of fluid management was followed in all three patients before and after ECMO initiation \[[@B20]\]. Moreover, a liberal strategy of fluid management in acute lung injury has been previously associated with prolonged duration of mechanical ventilation and intensive care \[[@B21]\].

ECMO is not without risks and there are no definitive criteria for ECMO treatment in adult ARDS. Therefore, ECMO should only be considered in adult patients with malaria and severe ARDS refractory to conventional treatment. The recently conducted CESAR trial showed favourable results of ECMO referral for adult patients with severe ARDS \[[@B8]\]. In that context, the same inclusion (Murray score \>3.0 or pH \<7.20) and exclusion (high pressure (\>30 cm H~2~O of peak inspiratory pressure) or high FiO~2~ (\>0.8) ventilation for more than seven days; intracranial bleeding; any other contraindication to limited heparinization) criteria for ECMO consideration in malaria and severe ARDS were used in the present case series.

Severe imported malaria is an important problem in the western world due to the increasing number of travellers returning from endemic countries who are non-adherent to malaria chemoprophylaxis \[[@B22]\]. Most imported cases occur in non-immune patients in whom malaria can rapidly progress to severe disease, with mortality as high as 20 to 35%, even with adequate anti-malarial treatment \[[@B23]\]. ARDS may develop in isolation or as part of a severe multisystem illness and often occurs within a few days of starting treatment when parasitaemia is falling \[[@B24]\]. The pathogenesis of ARDS in malaria is not fully understood, though it may involve parasite sequestration in the pulmonary vasculature and up-regulation of pro-inflammatory cytokines, and may persist even after parasite clearance \[[@B1]\]. However, parasite sequestration in the pulmonary vasculature seems to be relevant only for *P. falciparum* infection, given that in *P. vivax* malaria there is no substantial lung sequestration. Severe ARDS in patients with malaria has a poor prognosis, with mortality as high as 69 to 95% in observational ICU case series \[[@B22],[@B25]\]. Severe ARDS most commonly complicates *P. falciparum* infection and is rarely a complication of *P. vivax* or *P. ovale* infection. This could be related to differences in cyto-adhesion of infected erythrocytes \[[@B26]-[@B29]\]. However, it should be stressed that it is difficult to definitely establish malaria as the sole etiology for severe ARDS, fully excluding bacterial co-infection. Nevertheless, no documentation of bacterial co-infection was found despite extensive microbiology specimen collection and culture at ICU admission. This could support the assumption that malaria was the most probable cause for severe ARDS in the three cases presented in this report.

Risk factors associated with the development of ARDS in malaria include advanced age, lack of specific immunity, immunocompromised status, and pregnancy. A high parasitic burden is not necessary \[[@B30]\]. In this case series, patients were either semi-immune or non-immune and parasitaemia was less than 4% in all patients.

There are only two prior cases reported separately on the use of ECMO for severe ARDS in patients with malaria, as well as one case on the use of extracorporeal carbon dioxide elimination \[[@B5],[@B12],[@B13]\]. In both cases of ECMO use, *P. falciparum* was identified as the causal organism and ECMO was instituted within seven days for refractory hypoxaemia, but only one patient survived \[[@B5],[@B12]\]. In the case of extracorporeal carbon elimination use, *P. falciparum* was also identified as the causal organism and extracorporeal carbon elimination was instituted on the 17^th^ day, being discontinued after twelve days. The patient was weaned from mechanical ventilation and successfully discharged home \[[@B13]\]. In the present case series, one of the two patients that initiated ECMO after more than seven days of IMV did not survive. Patients with ARDS who have been receiving IMV with excessively high plateau pressures or high fractions of inspired oxygen for more than seven days may be less likely to benefit from ECMO \[[@B31]-[@B35]\]. Earlier initiation of ECMO, for these or other reasons, has been associated with better outcomes in some, but not all, observational studies \[[@B33],[@B36]-[@B38]\].

Patients with severe forms of malaria are highly susceptible to bacterial infections and concomitant antibacterial therapy is recommended \[[@B2],[@B39]\]. All the three patients presented in this case series received adequate antimicrobial therapy, though one patient developed nosocomial infections and ultimately died of sepsis, despite appropriate antibacterial coverage.

ECMO-related complications in the present case series included cannula migration into a hepatic vein, which was identified by transesophageal echocardiogram and corrected at the bedside. Thrombus formation in the oxygenator was ultimately the cause for oxygenator exchange in one patient. However, the rate of thrombosis-associated oxygenator failure requiring device exchange is low, even at low levels of anticoagulation \[[@B14]\]. Major bleeding complications, as occurred in one patient, are less frequent in the era of modern ECMO technology, given the ability to maintain circuit integrity at lower levels of anticoagulation, but they may still occur, especially in the setting of pre-existing thrombocytopaenia or coagulopathy.

In conclusion, severe ARDS can complicate *P. falciparum*, *P. vivax*, and *P. ovale* infection. In regions where the technology is available, ECMO referral should be considered for patients with malaria complicated by severe ARDS refractory to conventional treatment. Taking into account the limited experience with ECMO in severe malaria yet, its use should be performed in experienced ECMO centers. In fact, severe malaria can cause haemolysis, disseminated intravascular coagulation and low platelets, which might be exaggerated by the use of extracorporeal devices.
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